European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C
Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.
The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.
You may be interested
Coronavirus Greece: New shock with 3,789 new cases, 847 intubated, 87 deathsPanos - Apr 21, 2021
Greece announced that the new laboratory-confirmed cases of coronavirus recorded in the last 24 hours are 3,789, of which 7 were identified after…
Mitsotakis from the “Iniohos” exercise: We are not naive before the new threats we face (photos)Panos - Apr 21, 2021
The Prime Minister Kyriakos Mitsotakis had the opportunity to see the diverse capabilities of the Armed Forces of Greece and…
Greece ranked among top 8 honeymoon destination on PinterestPanos - Apr 20, 2021
Greece is ranked among the top 8 honeymoon destinations in the world by users of the Pinterest platform, according to…